Glucotrack (Nasdaq:GCTK) announced that it expects FDA investigational device exemption for its long-term CBGM later this year.

JointMedica, a global leader in orthopedic innovation, announces the commencement of an Investigational Device Exemption (IDE) study for its Polymotion® Hip Resurfacing (PHR®) device. The IDE study ...

In 2024, ONWARD added 20 patents to its IP portfolio. It now has more than 150 issued patents, excluding EP country ...

Transformational 2024: successfully advanced from preclinical to clinical stage companyStrengthened leadership team to drive growth and advance ...

The company is first rolling out the use of the Volt system among European Union doctors who have already gained experience ...

MTF Biologics, a global nonprofit organization that saves and heals lives by advancing tissue and organ donation, ...

Abbott begins new Intravascular Lithotripsy trial to improve outcomes in patients with coronary artery disease: Abbott Park, Illinois Wednesday, March 26, 2025, 15:00 Hrs [IST] Ab ...

Abbott is officially bringing the noise—literally—by launching a clinical trial for its new intravascular lithotripsy (IVL) ...

The US Food and Drug Administration (FDA) has granted Abbott an investigational device exemption to evaluate the company’s ...

Abbott ABT has received the FDA’s investigational device exemption (IDE) for its Coronary Intravascular Lithotripsy (“IVL”) system to evaluate the treatment of severe calcification in coronary ...

Abbott received FDA investigational device exemption (IDE) approval for its coronary intravascular lithotripsy (IVL) system.